The FDA recorded a supplement dated 27 August 2026 to Dr Reddy's Laboratories' abbreviated new drug application for omeprazole. The record does not state its content; supplements to generic applications typically concern manufacturing, packaging or labelling alignment with the reference product.
Nothing changes for prescribing. It is a reasonable moment to review long-term proton pump inhibitor use, which is often continued without a current indication.
- This is a supplement to an existing generic, not a new approval or safety signal.
- Omeprazole dosing and indications are unchanged.
- Review every long-term PPI prescription for a current indication.
- Continue PPIs where clearly indicated, such as gastroprotection in high-risk patients on antiplatelets or anticoagulants.
Why it matters
Generic supply from Indian manufacturers underpins PPI access worldwide.
Don't overread it
A licence supplement to a generic is not a new indication or safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for gastroenterology & hepatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free